

# Johannes C Van Der Mijn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/24713/publications.pdf>

Version: 2024-02-01

23  
papers

373  
citations

840728

11  
h-index

940516

16  
g-index

23  
all docs

23  
docs citations

23  
times ranked

832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel drugs that target the metabolic reprogramming in renal cell cancer. <i>Cancer &amp; Metabolism</i> , 2016, 4, 14.	5.0	64
2	Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms. <i>Drug Resistance Updates</i> , 2014, 17, 77-88.	14.4	56
3	Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. <i>Journal of Proteomics</i> , 2015, 127, 259-263.	2.4	43
4	Sunitinib activates Axl signaling in renal cell cancer. <i>International Journal of Cancer</i> , 2016, 138, 3002-3010.	5.1	32
5	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. <i>Journal of Proteomics</i> , 2017, 162, 99-107.	2.4	31
6	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. <i>Journal of Extracellular Vesicles</i> , 2014, 3, 25657.	12.2	29
7	Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. <i>Experimental and Molecular Medicine</i> , 2016, 48, e279-e279.	7.7	22
8	Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1 $\alpha$ -Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2020, 13, 177-185.	3.7	22
9	Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies. <i>Oncologist</i> , 2014, 19, 1028-1039.	3.7	21
10	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 221-230.	2.9	13
11	Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series. <i>PLoS ONE</i> , 2019, 14, e0226285.	2.5	12
12	NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1383-1389.	2.6	10
13	Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study. <i>Journal of Urology</i> , 2019, 202, 1248-1254.	0.4	9
14	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. <i>Molecular Oncology</i> , 2022, 16, 2384-2395.	4.6	5
15	Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. <i>Oncologist</i> , 2018, 23, 1135.	3.7	2
16	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11087-11087.	1.6	2
17	Mass spectrometry-based serum and plasma peptide profiling for prediction of treatment outcome in patients with cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22221-e22221.	1.6	0
18	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11609-11609.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Reply by Authors. Journal of Urology, 2019, 202, 1253-1254.	0.4	0
20	Title is missing!. , 2019, 14, e0226285.		0
21	Title is missing!. , 2019, 14, e0226285.		0
22	Title is missing!. , 2019, 14, e0226285.		0
23	Title is missing!. , 2019, 14, e0226285.		0